<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140478</url>
  </required_header>
  <id_info>
    <org_study_id>04-249</org_study_id>
    <nct_id>NCT00140478</nct_id>
  </id_info>
  <brief_title>Mifepristone (RU-486) in Androgen Independent Prostate Cancer</brief_title>
  <official_title>A Phase II Study of Mifepristone (RU-486) in Androgen Independent Prostate Cancer With Correlative Assessment of Androgen Receptor Co-Repressor Proteins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects (good and bad) that mifepristone has on
      patients with androgen independent prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive mifepristone, 200mg orally once a day. One treatment cycle is 28 days
      long. Patients will remain on treatment unless their cancer gets worse or they develop
      intolerable side effects.

      At the end of each cycle a physical examination, routine blood tests, and hormone levels will
      be performed.

      After every 3 cycles, one or more of the following will be performed: bone scan, chest x-ray,
      CT scan or MRI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the therapeutic efficacy of mifepristone in patients with androgen independent prostate cancer</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the duration of response, time to disease progression and safety of mifepristone in patients with androgen independent prostate cancer</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Adenocarcinoma of Prostate</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>200mg orally once daily</description>
    <other_name>RU-486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic documentation of adenocarcinoma of the prostate

          -  Bone metastasis(es) by bone scan or cat scan

          -  Clinical, biochemical, or radiographic progression after primary androgen ablation
             with either orchiectomy or gonadotropin releasing hormone analog therapy.

          -  One prior chemotherapy treatment is allowed.

          -  &gt; 3 weeks since major surgery

          -  &gt; 4 weeks since radiotherapy

          -  &gt; 8 weeks since prior strontium-89 or samarium 153

          -  ECOG performance status 0 or 1

          -  Absolute neutrophil count (ANC) &gt; 1,500/ul

          -  Platelets &gt; 100,000/ul

          -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)

          -  AST or ALT &lt; 3 x ULN

          -  Creatinine &lt; 1.5 x ULN

          -  Electrolytes within 10% of normal range

          -  Serum testosterone &lt; 50ng/dL

          -  Prostate-specific antigen (PSA) &gt; 5.0ng/ml

        Exclusion Criteria:

          -  Concomitant therapy with corticosteroids

          -  Chemotherapy within 28 days

          -  Currently active second malignancy other than non-melanoma skin cancer

          -  Baseline adrenal insufficiency requiring long-term steroids
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary-Ellen Taplin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>December 7, 2009</last_update_submitted>
  <last_update_submitted_qc>December 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mary-Ellen Taplin</name_title>
    <organization>Dana-Farber Cancer Institute</organization>
  </responsible_party>
  <keyword>Androgen Independent Prostate Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>RU-486</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

